Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference

On July 30, 2024 Tvardi Therapeutics, Inc. ("Tvardi"), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, reported that Imran Alibhai, PhD, Chief Executive Officer of Tvardi Therapeutics will participate in a fireside chat at the 2024 BTIG Virtual Biotechnology Conference on Tuesday, August 6, 2024, at 10:00 AM ET (Press release, Tvardi Therapeutics, JUL 31, 2024, View Source [SID1234645173]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the fireside chat, the management team will hold one-on-one investor meetings Monday and Tuesday, August 5-6, 2024. If you are interested in meeting with the Tvardi Therapeutics management team during the conference, please reach out to BTIG.

Consolidated Financial Results for the Three-month Period Ended June 30, 2024

On July 30, 2024 NEC reported consolidated Financial Results for the Three-month Period Ended June 30, 2024 (Press release, NEC, JUL 30, 2024, View Source [SID1234647173]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Leidos Holdings, Inc. Reports Second Quarter Fiscal Year 2024 Results

On July 30, 2024 Leidos Holdings, Inc., a FORTUNE 500 innovation company, reported financial results for the second quarter of fiscal year 2024 (Press release, Leidos, JUL 30, 2024, View Source [SID1234647129]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thomas Bell, Leidos Chief Executive Officer, commented, "In the second quarter, Leidos continued its industry-leading profitable growth and strong cash generation, showcasing the progress we’ve made towards our key operational priorities and the dedication to our "Promises Made, Promises Kept" philosophy. Our collaborative innovation strategy and capabilities-based organization position us well to deliver on our commitments for the remainder of 2024 and beyond."

Second quarter earnings 2024

On July 30, 2024 Hanmi reported its second quarter 2024 results (Presentation, Hanmi, JUL 30, 2024, View Source [SID1234646098]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Takeda Quarterly Financial Report For the Quarter Ended June 30, 2024

On July 30, 2024 Takeda reported its Financial Report For the Quarter Ended June 30, 2024 (Presentation, Takeda, JUL 30, 2024, View Source [SID1234645449]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!